Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNYNF) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Sanofi (SNYNF) over the last 17 years, with Q4 2025 value amounting to $8.6 billion.

  • Sanofi's Accounts Payables rose 620.08% to $8.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.6 billion, marking a year-over-year increase of 620.08%. This contributed to the annual value of $8.3 billion for FY2025, which is 178.58% up from last year.
  • Sanofi's Accounts Payables amounted to $8.6 billion in Q4 2025, which was up 620.08% from $8.0 billion recorded in Q2 2025.
  • In the past 5 years, Sanofi's Accounts Payables ranged from a high of $8.6 billion in Q4 2025 and a low of $6.5 billion during Q2 2021
  • For the 5-year period, Sanofi's Accounts Payables averaged around $7.6 billion, with its median value being $7.9 billion (2023).
  • In the last 5 years, Sanofi's Accounts Payables surged by 1942.31% in 2021 and then crashed by 168.04% in 2022.
  • Quarter analysis of 5 years shows Sanofi's Accounts Payables stood at $7.1 billion in 2021, then decreased by 1.68% to $7.0 billion in 2022, then increased by 13.43% to $7.9 billion in 2023, then rose by 2.34% to $8.1 billion in 2024, then increased by 6.2% to $8.6 billion in 2025.
  • Its Accounts Payables was $8.6 billion in Q4 2025, compared to $8.0 billion in Q2 2025 and $8.1 billion in Q4 2024.